Welcome to our dedicated page for CTS SEC filings (Ticker: CTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CTS Corporation filings document operating results, Regulation FD investor materials and governance disclosures for a manufacturer of sensors, actuators and electronic components. Form 8-K reports furnish quarterly and annual earnings releases, webcast slides and investor presentations tied to the company's end-market strategy and financial outlook.
CTS regulatory filings also cover proxy governance and compensation matters, board and executive officer changes, material agreements, and financing arrangements, including an unsecured revolving credit facility. These records describe the company's capital structure, leadership, treatment of furnished materials under the Exchange Act and risk language for forward-looking statements.
CTS Corp reported an initial statement of beneficial ownership by a director. The filing lists 3,500 common shares held directly as of 11/06/2025. The footnote states that certain restricted stock units vest 100% on the first anniversary of the grant date, contingent on continued service as a director through the vesting date.
CTS Corporation (CTS) reported a routine director equity award. On 11/06/2025, a director acquired 3,500 shares at $0, reported as a grant tied to restricted stock units. The filing notes these RSUs vest 100% on the first anniversary of the grant date, contingent on continued service as a director through the vesting date.
Following the transaction, the reporting person beneficially owns 46,700 shares, held directly. No derivative securities were listed.
CTS Corporation (CTS) disclosed a Form 4 for director Amy M. Dodrill. On 11/06/2025, she acquired 3,500 shares of common stock at $0, reported as a grant of restricted stock units that vest 100% on the first anniversary of the grant date, contingent on continued service as a director. After this transaction, her beneficial ownership stands at 8,800 shares, held directly.
CTS Corp (CTS) director Donna Costello reported an equity award on a Form 4. On 11/06/2025, she acquired 3,500 shares of common stock at $0 (code A). Following the transaction, her beneficial ownership stands at 19,500 shares, held directly.
The filing notes these were restricted stock units that vest 100% on the first anniversary of the grant date, contingent on her continued service as a director through the vesting date.
CTS Corporation expanded its Board of Directors from seven to eight members and elected Kimberly MacKay to fill the new seat, effective November 5, 2025. MacKay serves as SVP, General Counsel and Corporate Secretary of West Pharmaceutical Services and will join CTS’s Nominating, Governance and Sustainability Committee and Technology and Transactions Committee.
As a non-employee director, she will receive compensation consistent with other non-employee directors as described in the Company’s March 28, 2025 proxy statement. The Company reported no arrangements leading to her selection and no related person transactions requiring disclosure under Item 404(a). CTS will enter into its standard indemnification agreement with her, and a related press release was furnished as Exhibit 99.1 on November 6, 2025.
CTS Corporation (NYSE: CTS) reported Q3 2025 results. Net sales were $142.97M, up from $132.38M a year ago, driven by Industrial ($37.10M vs $30.75M), Medical ($21.96M vs $18.02M), and Aerospace & Defense ($25.36M vs $20.59M), while Transportation softened ($58.55M vs $63.03M). Operating earnings were essentially flat at $20.94M. Net earnings were $13.69M vs $18.08M, with diluted EPS of $0.46 vs $0.59 as higher SG&A and R&D offset gross profit gains.
Year to date, sales reached $404.05M vs $388.30M and net earnings were $45.58M vs $43.91M (diluted EPS $1.52 vs $1.43). Cash provided by operations was $72.89M, ending cash was $110.30M, and long‑term debt was $90.70M (weighted average rate 5.56%). The company repurchased 399,500 shares for $16.74M in Q3 and $40.08M year to date, with approximately $21.34M remaining under its program. Remediation reserves increased to $15.90M; for the Asheville, NC matter, the company recorded a $5.97M loss estimate within an updated exposure range of $5.97M to $8.29M. Shares outstanding were 29,052,423 as of October 21, 2025.
CTS Corporation furnished an investor presentation under Item 7.01 (Regulation FD) in a Form 8‑K. The presentation, included as Exhibit 99.1 and dated October 2025, may be used in meetings with investors and analysts during the fiscal year ended December 31, 2025. The company states the materials are furnished, not filed, and are not subject to Section 18 liability or incorporated by reference unless specifically referenced.
CTS Corporation furnished an update on its business by providing a press release with certain results for the third quarter ended September 30, 2025, and related presentation materials. The company also announced a live webcast on October 28, 2025 to discuss these results.
The materials are furnished under Items 2.02 and 7.01 and are not deemed filed under the Exchange Act. Attached exhibits include the earnings release (Exhibit 99.1), the Q3 2025 slide deck (Exhibit 99.2), and the cover page interactive data file (Exhibit 104).
BlackRock, Inc. filed Amendment No. 5 to Schedule 13G reporting beneficial ownership of CTS CORP common stock. BlackRock reports 4,334,951 shares beneficially owned, representing 14.7% of the class as of the event date 09/30/2025.
BlackRock has sole voting power over 4,265,805 shares and sole dispositive power over 4,334,951 shares, with no shared voting or dispositive power. The filing states the securities are held in the ordinary course and not for the purpose of changing or influencing control. The filing also notes that iShares Core S&P Small-Cap ETF has an interest of more than five percent of CTS CORP’s outstanding common stock.
EARNEST Partners, LLC reports beneficial ownership of 1,976,058 shares of CTS Corp common stock, representing 6.7% of the class as of the reported event. The filing shows EARNEST holds sole dispositive power over all 1,976,058 shares and sole voting power over 1,337,689 shares, with shared voting power for 188,130 shares. The firm is filing as an investment adviser and states that no single client account holds more than 5% of the class. The filing includes a certification that the shares were acquired in the ordinary course of business and are not intended to influence control of the issuer.